Compare AVNW & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | NKTX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.6M | 129.3M |
| IPO Year | 2007 | 2020 |
| Metric | AVNW | NKTX |
|---|---|---|
| Price | $21.41 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $32.50 | $13.25 |
| AVG Volume (30 Days) | 104.2K | ★ 681.0K |
| Earning Date | 02-03-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $453,497,000.00 | N/A |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $20.76 | ★ N/A |
| Revenue Growth | ★ 10.72 | N/A |
| 52 Week Low | $15.80 | $1.31 |
| 52 Week High | $26.83 | $2.74 |
| Indicator | AVNW | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 45.33 |
| Support Level | $20.77 | $1.70 |
| Resistance Level | $21.83 | $1.90 |
| Average True Range (ATR) | 0.72 | 0.07 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 57.51 | 55.00 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.